The Role of Biosimilars

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Biologics are increasingly going off-patent, necessitating the integration of biosimilars into clinical practice.
• Biosimilars are highly similar to reference biologic agents, approved based on demonstrating "near fingerprint identity" in structure and potency.
• The introduction of biosimilars is anticipated to enhance market competition and decrease overall treatment expenditures.

Purpose of the Study:

• To review the incorporation of biosimilars into oncology treatment guidelines.
• To discuss the development, approval, and clinical recommendations for biosimilars and related agents.
• To clarify the use of specific myeloid growth factors, including biosimilars and true biologic agents.

Main Methods:

• Review of NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Myeloid Growth Factors.
• Presentation of an overview of biosimilar development and approval processes.
• Discussion of clinical recommendations for filgrastim-sndz and tbo-filgrastim.

Main Results:

• The NCCN Guidelines for Myeloid Growth Factors have been updated to include recommendations for filgrastim-sndz, the first US-approved biosimilar.
• Presentations covered the regulatory pathway for biosimilars and their clinical application.
• The distinct indications for tbo-filgrastim compared to other growth factors were highlighted, noting potential for confusion.

Conclusions:

• Biosimilars are being actively incorporated into oncology guidelines, such as the NCCN Guidelines.
• Understanding the nuances of biosimilar approval and specific agent indications is crucial for effective clinical implementation.
• The integration of biosimilars like filgrastim-sndz aims to improve patient access and manage healthcare costs in oncology.